Based on the Crinetics Pharmaceuticals Inc stock forecast from 8 analysts, the average analyst target price for Crinetics Pharmaceuticals Inc is USD 76.71 over the next 12 months. Crinetics Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Crinetics Pharmaceuticals Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Crinetics Pharmaceuticals Inc’s stock price was USD 52.74. Crinetics Pharmaceuticals Inc’s stock price has changed by -5.18% over the past week, -4.40% over the past month and +42.27% over the last year.
No recent analyst target price found for Crinetics Pharmaceuticals Inc
No recent average analyst rating found for Crinetics Pharmaceuticals Inc
Company Overview Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Read Less
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral sele...Read More
Frequently Asked Questions About Crinetics Pharmaceuticals Inc (CRNX) Stock
Based on ratings from 8 analysts Crinetics Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 14 buy, sell and hold ratings.
Unfortunately we do not have enough data on CRNX's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for CRNX is USD 76.71 over the next 12 months. The maximum analyst target price is USD 97 while the minimum anlayst target price is USD 54.
Unfortunately we do not have enough data on CRNX's stock to indicate if its overvalued.
The last closing price of CRNX's stock was USD 52.74.
The most recent market capitalization for CRNX is USD 5.30B.
Based on targets from 8 analysts, the average taret price for CRNX is projected at USD 76.71 over the next 12 months.
This means that CRNX's stock price may go up by +45.46% over the next 12 months.
We can't find any ETFs which contains Crinetics Pharmaceuticals Inc's stock.
As per our most recent records Crinetics Pharmaceuticals Inc has 290 Employees.
Crinetics Pharmaceuticals Inc's registered address is 6055 Lusk Boulevard, San Diego, CA, United States, 92121.
You can get more information about it from Crinetics Pharmaceuticals Inc's website at https://www.crinetics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Crinetics Pharmaceuticals Inc (CRNX) Stock
Based on ratings from 8 analysts Crinetics Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 14 buy, sell and hold ratings.
Unfortunately we do not have enough data on CRNX's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for CRNX is USD 76.71 over the next 12 months. The maximum analyst target price is USD 97 while the minimum anlayst target price is USD 54.
Unfortunately we do not have enough data on CRNX's stock to indicate if its overvalued.
The last closing price of CRNX's stock was USD 52.74.
The most recent market capitalization for CRNX is USD 5.30B.
Based on targets from 8 analysts, the average taret price for CRNX is projected at USD 76.71 over the next 12 months.
This means that CRNX's stock price may go up by +45.46% over the next 12 months.
We can't find any ETFs which contains Crinetics Pharmaceuticals Inc's stock.
As per our most recent records Crinetics Pharmaceuticals Inc has 290 Employees.
Crinetics Pharmaceuticals Inc's registered address is 6055 Lusk Boulevard, San Diego, CA, United States, 92121.
You can get more information about it from Crinetics Pharmaceuticals Inc's website at https://www.crinetics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CRNX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
